NCT06790160Active, not recruiting
Study of Patients Being Treated With Anti-obesity Medication
Observational Study of Patients Being Treated With Anti-obesity Medication
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
The goal of this observational study is to learn about the real-world effects of selected obesity medications in adults undergoing medical weight management. The main outcomes of interest are changes in body composition, routine clinical markers, muscular performance, and nutritional intake over the course of treatment. Additionally, the influence of lifestyle factors on changes in these outcome variables will be examined. Participants beginning treatment with selected obesity medications will undergo periodic body composition and muscular performance testing, as well as complete online surveys about their nutritional intake and physical activity and exercise participation. Additionally, routinely collected clinical information will be evaluated.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 17 Jan 2025
- Start date
- 31 Jan 2025
- Primary completion date
- Mar 2028
- Lead sponsor
- Texas Tech University
- Diseases
- Obesity
- NCT number
- NCT06790160
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 31 Jan 2025 to the primary completion date, Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with type 2 diabetes.
Other
- Patients who report not being willing or able to complete the assessments included in this research study.
- Patients who are currently pregnant or trying to become pregnant.
Who the study is looking for
- Patient who is beginning treatment through Vineyard Virtual Health Clinic using semaglutide or tirzepatide. While the physician will individualize the treatment plans, the criteria for these medications will include, at a minimum: (A) a body mass index ≥30 kg/m2; OR (B) a BMI ≥27 kg/m2 plus at least one comorbidity.
- Patient who lives in drivable proximity to a city with an accepted DXA testing facility and is willing to report to the facility for periodic body composition testing.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Texas Tech University Coordinator of this site? Confirm its status | Lubbock | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.